Audit: QRS - Indole-3-Carbinol for Health & Longevity

Audit conducted on 13/09/2026 04:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traced to ER text: protocol cells to ER Therapeutic Protocol (lines 384, 392, 398), time cells to ER Practical Considerations line 443, benefit/risk items to ER tier headings, monitoring rows to the ER biomarker table (lines 473–480), cadence to ER line 469, qualitative items to ER lines 484–489.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“suspected thyroid-suppressing effect”, “No established target”, “No supplement-specific target” all carried over verbatim from the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Tamoxifen remains a contraindication rather than being demoted to an interaction; thresholds (TSH > 4.0 mIU/L, transaminases > 2× ULN, 10 days pre-surgery) are unaltered.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER avoid-list, interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor appears on the sheet.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names (e.g., BioResponse DIM, Thorne) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The sober, sceptical register of the ER Conclusion is mirrored in the At-A-Glance and throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Presents thresholds, dose ceilings and monitoring ranges that enable an informed decision without editorialising.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as evidence and observation, not instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advisory constructions in the QRS’s own voice; the only imperative phrasings are ER-verbatim biomarker target cells and the fixed template disclaimer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “must” in the QRS voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns; ER line 489 (“For anyone using it…”) was recast impersonally as “Where a visible lesion motivated use…” (line 719).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to unavoidable biomarker and tier-heading names; the lede is jargon-free.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, benefit and risk tiers carry the key fact only; trailing mechanistic clauses are stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by text extraction: no “you”/”your” anywhere in rendered content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Contraindication thresholds, drug-monitoring requirements and an eight-marker panel presume a risk-aware, proactive reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Laboratory panels at baseline, 12 weeks, 6 and 12 months plus plasma drug-level checks are presented without hedging about burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward a general-population reader; CYP1A2 substrate handling and metabolite-ratio tracking are presented directly.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance foregrounds the drug-clearance liability, the signal that matters most to a supplement-using, medication-taking audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“longevity” used in both the title and the lede; “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route of administration is “Taken orally” (line 450), not “by mouth”; “medications”, “adverse” terminology and “transaminases” used in clinical register.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Line-by-line diff against [qrs_template] shows zero changes outside the variable spans; all fixed headings, gate headings, tier labels and column headers are byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 named template spans present; the marker_#_* and qualitative_item_# patterns are instantiated as marker_1–marker_8 and qualitative_item_1–qualitative_item_6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans, the footer disclaimer and the whole style block are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section drawn on by the QRS is empty; the High benefit tier carries an explanatory statement rather than an empty-state phrase, and is handled under 12.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose”, “Timing” and “Split versus single dose” are the ER’s bold labels verbatim (ER lines 384, 392, 398); monitoring row labels are the ER biomarker names verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No existing ER label was replaced by a paraphrase; the three time-to-effect labels are derived as required by 11.4 from the single ER “Time to effect” bullet, using the ER’s own wording.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Programmatic scan of the rendered text returns no emoji code points; ER tier emoji and the “⚠️ Conflicted” markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: benefit and risk tiers carry headings only, gate items are reduced to the key fact, and no ER magnitude paragraphs, mitigations or modifying factors are carried over.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before any other comment or element.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” text on line 2 precedes the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated anywhere in <head> or <body>.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which its colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: indole_3_carbinol_2026-0913-0120_Opus_ER.md, matching the ER frontmatter filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the version badge of [qrs_prompt].
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0913-0454, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename on disk, indole_3_carbinol_2026-0913-0120_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys, including the added git_user and git_issue values.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Indole-3-Carbinol for Health & Longevity - Quick Reference Sheet, with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Indole-3-Carbinol for Health & Longevity, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/13/2026, the correct reformatting of 2026-0913-0454.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line and prompt version are absent.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 condenses ER Conclusion lines 511–515: the two reliable effects, the thin lesion evidence, the cell/mouse basis of longevity claims, and the drug-clearance liability.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words, verified by word count.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct ER Conclusion sentence (lines 511, 513, 515).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “estrogen”, “liver enzyme system”, “cell and mouse work” replace CYP1A2, DIM and 2-hydroxylation.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind in the lede.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items come from the “Populations who should avoid Indole-3-Carbinol” list in that ER section (lines 353–360).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER avoid-list entries are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–549: eight well-formed <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The pregnancy bullet’s trailing clause (“— no human safety data, and the compound crosses into fetal tissue in animal studies”) is stripped; the leading “People with/on” wrappers are dropped; no dashes remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“above 4.0 mIU/L”, “above twice the upper limit of normal”, “within 10 days of planned surgery”, “without therapeutic drug monitoring”, “under active endocrine treatment” and “outside a supervised trial protocol” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER avoid-list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names eight such populations and the section is correspondingly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to bullets in that ER section (lines 335–349).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Tamoxifen, the CYP1A2 antipsychotics and theophylline/tizanidine are correctly omitted because they appear in [stop_items]; the remaining eight ER interactions are all present.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 557–564: eight well-formed <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All ER mechanism and mitigation sentences are dropped, and the em-dashed severity tags (“— monitor”, “— caution”) on the warfarin, estrogen and acid-suppression bullets are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Drug examples “(apixaban, rivaroxaban)”, “(estradiol, ethinylestradiol)”, “(omeprazole, famotidine)” and severity tags “(caution, additive)”, “(caution)”, “(minor)” are all retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists eleven interactions and the section is correspondingly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol bullets at lines 384 (“Standard dose”), 392 (“Timing”) and 398 (“Split versus single dose”).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, administration with food (which governs whether the active metabolite forms at all) and dosing frequency are the three decision-bearing aspects; the remaining ER bullets are contextual or pharmacokinetic.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section provides thirteen bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans (lines 444–472) carry substantive ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The three aspects named in ER line 443 — 12 weeks for cervical lesions, 3–6 months for airway and vulvar protocols, within one month for the metabolic shift — are each given a cell.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Cervical lesion regression is the ER’s only Medium benefit and comes first; the vulvar and airway benefits are Low and come second; the estrogen metabolite shift is Speculative and comes last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans (lines 483–511) carry substantive ER-derived content; no placeholders remain.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at line 443, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten listed items are ER Expected Benefits sub-headings (lines 157–209).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 521, 524, 527 and 530.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; every ER magnitude paragraph, relative risk, confidence interval and citation is omitted, and the “⚠️ Conflicted” qualifiers are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER line 153 states no benefit reaches High; [benefits_high] is set to style="display: none" with no empty-state text (line 521).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All twelve listed items are ER Potential Risks & Side Effects sub-headings (lines 237–307).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 576, 579, 582 and 585.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; the 4.1-fold induction figure, SHBG deltas, adverse-event percentages and all citations are omitted, and “⚠️ Conflicted” markers are stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four risk spans.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no risk span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows and the cadence derive from the ER Monitoring Protocol & Defining Success section (lines 469–480).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarker rows present — ALT, AST, TSH, Free T4, sex hormone-binding globulin, free testosterone, the urinary 2-hydroxyestrone : 16α-hydroxyestrone ratio and plasma CYP1A2-substrate drug level — with ER-verbatim targets and reasons.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 695 condenses ER line 469: liver and thyroid panels at baseline, 12 weeks, 6 and 12 months; hormone measures at 12 weeks; substrate drug levels 2 weeks after starting and stopping.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (lines 484–489).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, with the ER’s explanatory trailing clauses trimmed and the final one recast impersonally.

Issues 13/09/2026 04:57

Pass rate 100.00%. No issues found.